New drug takes on KRAS: early trial launches for Hard-to-Treat cancers

NCT ID NCT04111458

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The main goals are to find a safe dose and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1701963 (a KRAS-blocking drug) and trametinib (a MEK inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have a KRAS mutation.
What could go wrong: This is a very early (Phase 1) trial testing a new drug in humans for the first time. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS, KRAS MUTATION; SOS1

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Erasmus Medisch Centrum-ROTTERDAM-50697

Rotterdam, 3015 GD, Netherlands
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Sarah Cannon Research Institute-Nashville-48456

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
Universitätsklinikum Frankfurt

Frankfurt am Main, 60590, Germany
Universitätsklinikum Köln (AöR)

Cologne, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.